XERS Xeris Pharmaceuticals Inc.

-0.26  -3%
Previous Close 9.6
Open 9.55
Price To Book 3.34
Market Cap 251721929
Shares 26,936,536
Volume 24,440
Short Ratio
Av. Daily Volume 345,709

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due 2H 2019.
Continuous glucagon
Hypoglycemia-Associated Autonomic Failure
Phase 3 trial to be initiated 1H 2019.
Continuous glucagon
Congenital Hyperinsulinism
Phase 2 data due 2H 2019.
Self administered glucagon
Exercise-Induced Hypoglycemia
Phase 2 data due 1H 2019.
Self administered glucagon
Post-Bariatric Hypoglycemia
PDUFA date June 10, 2018.
Glucagon Rescue Pen
Severe hypoglycemia

Latest News

  1. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  2. Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
  3. Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
  4. How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?
  5. Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
  6. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  7. Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
  8. Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
  9. Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today
  10. The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
  11. Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock
  12. European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)
  13. Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress
  14. Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen
  15. Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon
  16. Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen